[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors]

Area of Science:

• Hematology
• Oncology
• Neurology

Background:

• Central nervous system (CNS) involvement by lymphoma is a serious complication with a poor prognosis.
• Identifying risk factors for CNS relapse is crucial for guiding prophylactic treatment strategies.

Purpose of the Study:

• To review and synthesize current knowledge on CNS relapse risk factors in lymphoma.
• To inform decisions regarding CNS prophylaxis, particularly in diffuse large B-cell lymphoma (DLBCL).

Main Methods:

• Review of extensive, primarily retrospective, and heterogeneous studies on CNS involvement in lymphoma.
• Analysis of risk factors including lymphoma subtype, treatment regimens, and specific clinical indicators.

Main Results:

• Aggressive lymphomas (e.g., lymphoblastic, Burkitt's) have high CNS relapse rates (25-30%) mandating prophylaxis.
• Rituximab-based immunochemotherapy may reduce CNS relapse rates in DLBCL.
• Increased LDH, multiple extranodal sites, and testicular or breast involvement are associated with higher CNS relapse risk.
• Renal or epidural space involvement and MYC rearrangements may warrant consideration for CNS prophylaxis in DLBCL.

Conclusions:

• CNS prophylaxis is essential for aggressive lymphomas and specific high-risk DLBCL patient groups.
• While certain factors increase risk, a universal prophylaxis strategy for all DLBCL patients is not yet established.
• Further research is needed to refine CNS prophylaxis guidelines for DLBCL, especially concerning MYC rearrangements and specific organ involvement.